Antiviral activities of Indonesian medicinal plants in the East Java region against hepatitis C virus

Virology Journal

Hak Hotta³  Chie Aoki¹  Lin Deng³  Ikuo Shoji³  Nobuo Kawahara²  Hiroyuki Fuchino²  Nasronudin⁴  Soetjipto⁴  Achmad Fuad⁵  Maria Inge Lusida⁴  Aty Widyawaruyanti⁵  Abdul Rahman⁵  Myrna Adianti³  Evhy Apriani⁴  Adita Ayu Permanasari⁴  Lydia Tumewu⁴  Tutik Sri Wahyuni³ 

[1] JST/JICA SATREPS, Kobe University Graduate School of Medicine, Kobe, Japan;Research Center for Medicinal Plant Resources, National Institute of Biomedical Innovation, Tsukuba, Ibaraki, Japan;Division of Microbiology, Kobe University Graduate School of Medicine, Kobe, Japan;Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia;Department of Pharmacognocy and Phytochemistry, Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia

关键词: Entry inhibition;    Indonesia;    Medicinal plants;    Antiviral activity;    HCV;    Hepatitis C virus;   

Others  :  826141
DOI  :  10.1186/1743-422X-10-259

 received in 2013-06-01, accepted in 2013-08-09,  发布年份 2013

【 摘 要 】

Background

Hepatitis C virus (HCV) is a major cause of liver disease and a potential cause of substantial morbidity and mortality worldwide. The overall prevalence of HCV infection is 2%, representing 120 million people worldwide. Current standard treatment using pegylated interferon and ribavirin is effective in only 50% of the patients infected with HCV genotype 1, and is associated with significant side effects. Therefore, it is still of importance to develop new drugs for treatment of HCV. Antiviral substances obtained from natural products, including medicinal plants, are potentially good targets to study. In this study, we evaluated Indonesian medicinal plants for their anti-HCV activities.

Methods

Ethanol extracts of 21 samples derived from 17 species of medicinal plants explored in the East Java region were tested. Anti-HCV activities were determined by a cell culture method using Huh7.5 cells and HCV strains of 9 different genotypes (1a to 7a, 1b and 2b).

Results

Four of the 21 samples tested showed antiviral activities against HCV: Toona sureni leaves (TSL) with 50% inhibitory concentrations (IC₅₀) of 13.9 and 2.0 μg/ml against the HCV J6/JFH1-P47 and -P1 strains, respectively, Melicope latifolia leaves (MLL) with IC₅₀ of 3.5 and 2.1 μg/ml, respectively, Melanolepis multiglandulosa stem (MMS) with IC₅₀ of 17.1 and 6.2 μg/ml, respectively, and Ficus fistulosa leaves (FFL) with IC₅₀ of 15.0 and 5.7 μg/ml, respectively. Time-of-addition experiments revealed that TSL and MLL inhibited both at the entry and post-entry steps while MMS and FFL principally at the entry step. TSL and MLL inhibited all of 11 HCV strains of all the genotypes tested to the same extent. On the other hand, FFL showed significantly weaker inhibitory activities against the HCV genotype 1a strain, and MMS against the HCV strains of genotypes 2b and 7a to a lesser extent, compared to the other HCV genotypes.

Conclusions

Ethanol extracts of TSL, MLL, MMS and FFL showed antiviral activities against all the HCV genotypes tested with the exception that some genotype(s) showed significant resistance to FFL and to MMS to a lesser extent. These plant extracts may be good candidates for the development of anti-HCV drugs.

【 授权许可】

   
2013 Wahyuni et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Moradpour D, Penin F, Rice CM: Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5:453-463.
• [2]Ploss A, Dubuisson J: New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 2012, 61(Suppl 1):i25-i35.
• [3]Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J: Development and characterization of hepatitis C virus genotype 1–7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49:364-377.
• [4]Arzumanyan A, Reis HM, Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013, 13:123-135.
• [5]Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
• [6]Calland N, Dubuisson J, Rouille Y, Seron K: Hepatitis C virus and natural compounds: a new antiviral approach? Virus 2012, 4:2197-2217.
• [7]Jassim SA, Naji MA: Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol 2003, 95:412-427.
• [8]Hussein G, Miyashiro H, Nakamura N, Hattori M, Kakiuchi N, Shimotohno K: Inhibitory effects of sudanese medicinal plant extracts on hepatitis C virus (HCV) protease. Phytother Res 2000, 14:510-516.
• [9]Wu SF, Lin CK, Chuang YS, Chang FR, Tseng CK, Wu YC, Lee JC: Anti-hepatitis C virus activity of 3-hydroxy caruilignan C from Swietenia macrophylla stems. J Viral Hepat 2012, 19:364-370.
• [10]Ravikumar YS, Ray U, Nandhitha M, Perween A, Raja Naika H, Khanna N, Das S: Inhibition of hepatitis C virus replication by herbal extract: Phyllanthus amarus as potent natural source. Virus Res 2011, 158:89-97.
• [11]Khachatoorian R, Arumugaswami V, Raychaudhuri S, Yeh GK, Maloney EM, Wang J, Dasgupta A, French SW: Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle. Virology 2012, 433:346-355.
• [12]Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R: Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity. J Viral Hepat 2012, 19:e81-e88.
• [13]Nugraha AS, Keller PA: Revealing indigenous Indonesian traditional medicine: anti-infective agents. Nat Prod Commun 2011, 6:1953-1966.
• [14]Bungyoku Y, Shoji I, Makine T, Adachi T, Hayashida K, Nagano-Fujii M, Ide YH, Deng L, Hotta H: Efficient production of infectious hepatitis C virus with adaptive mutations in cultured hepatoma cells. J Gen Virol 2009, 90:1681-1691.
• [15]Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM: Complete replication of hepatitis C virus in cell culture. Science 2005, 309:623-626.
• [16]Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, et al.: Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005, 11:791-796.
• [17]Nawawi A, Nakamura N, Hattori M, Kurokawa M, Shiraki K: Inhibitory effects of Indonesian medicinal plants on the infection of herpes simplex virus type 1. Phytother Res 1999, 13:37-41.
• [18]O'Donnell F, Ramachandran VN, Smyth TJ, Smyth WF, Brooks P: An investigation of bioactive phytochemicals in the leaves of Melicope vitiflora by electrospray ionisation ion trap mass spectrometry. Anal Chim Acta 2009, 634:115-120.
• [19]Higa M, Imamura M, Ogihara K, Suzuka T: Isolation of five new flavonoids from Melicope triphylla. Chem Pharm Bull (Tokyo) 2013, 61:384-389.
• [20]Haid S, Novodomska A, Gentzsch J, Grethe C, Geuenich S, Bankwitz D, Chhatwal P, Jannack B, Hennebelle T, Bailleul F, et al.: A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes. Gastroenterology 2012, 14:213-222 e215.
• [21]Li Y, Yu S, Liu D, Proksch P, Lin W: Inhibitory effects of polyphenols toward HCV from the mangrove plant Excoecaria agallocha L. Bioorg Med Chem Lett 2012, 22:1099-1102.
• [22]Kuete V, Ngameni B, Simo CC, Tankeu RK, Ngadjui BT, Meyer JJ, Lall N, Kuiate JR: Antimicrobial activity of the crude extracts and compounds from Ficus chlamydocarpa and Ficus cordata (Moraceae). J Ethnopharmacol 2008, 120:17-24.
• [23]Lazreg Aref H, Gaaliche B, Fekih A, Mars M, Aouni M, Pierre Chaumon J, Said K: In vitro cytotoxic and antiviral activities of Ficus carica latex extracts. Nat Prod Res 2011, 25:310-319.
• [24]Yarmolinsky L, Zaccai M, Ben-Shabat S, Mills D, Huleihel M: Antiviral activity of ethanol extracts of Ficus binjamina and Lilium candidum in vitro. N Biotechnol 2009, 26:307-313.
• [25]Yarmolinsky L, Huleihel M, Zaccai M, Ben-Shabat S: Potent antiviral flavone glycosides from Ficus benjamina leaves. Fitoterapia 2012, 83:362-367.
• [26]Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouille Y, Seron K: (−)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 2012, 55:720-729.
• [27]Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, et al.: Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010, 51:1912-1921.
• [28]Barcena R, Moreno A, Rodriguez-Gandia MA, Albillos A, Arocena C, Blesa C, Garcia-Hoz F, Graus J, Nuno J, Lopez-Hervas P, et al.: Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J Hepatol 2013, 58:421-426.
• [29]Deng L, Adachi T, Kitayama K, Bungyoku Y, Kitazawa S, Ishido S, Shoji I, Hotta H: Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol 2008, 82:10375-10385.